Abstract
Background: Neuromyelitis optica spectrum disease (NMOSD) is a chronic inflammatory and usually relapsing demyelinating disease which mainly involves optic nerve and spinal cord and also other parts of the central nervous system (CNS). Rituximab has been used for some autoimmune neurological disorders. Early and aggressive immunosuppression therapy in NMOSD patients is necessary to prevent clinical relapses and permanent disability. Rituximab, a monoclonal antibody against b cells, has been found effective in several recent studies. The objective of this study is to evaluate the clinical efficacy of rituximab as a newly introduced treatment for NMOSD in Iran.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
